Since nanocarriers are able to encapsulate and deliver insoluble small molecules, antibodies, and nucleic acids such as miRNA and mRNA, EGFR-targeting nanocarriers can provide alternative therapeutic opportunities for patients with TNBC and other EGFR-overexpressing cancers. This evidence concerns the gene EGFR and cancer.